blood diseases

Pharma

'Commercial debate' looms over Blueprint's Ayvakit expansion

Although the new Ayvakit trial met all its primary and key secondary endpoints, the new patient symptom data marked a slump from an earlier study.
Angus Liu Aug 17, 2022 11:06am

Bluebird scores 2nd straight win at high-stakes FDA meeting

Jun 10, 2022 2:46pm

BMS' blockbuster ambitions for Reblozyl narrowed slightly Monday

Jun 6, 2022 11:09am

Drug delivery problems have prompted a new Teva recall

May 24, 2022 9:18am

Sanofi's new Enjaymo will limit transfusions for CAD patients

Feb 4, 2022 4:46pm

Vertex's Trikafta posted megablockbuster sales in 202

Jan 27, 2022 9:55am